4CPS-181 Study of the reasons for the therapeutic discontinuation of immune-based therapies in relapsing-remitting multiple sclerosis

BACKGROUND: Nowadays, 12 different therapies are available as immune-mediated therapies (IMT) for multiple sclerosis (MS) drugs. Guidelines classify these treatments as first- and second-line. This variety allows treatment discontinuations (TD) under situations different from those initially planned...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Eur J Hosp Pharm
Päätekijät: Rubio, S Marín, Font, M Miarons, Cordón, L Pérez, Ulayar, A Sanchez, Bernadas, L Campins, Maragall, C Agustí, Ferrer, M Camps, Roig, T Gurrera, Faixo, D Lopez
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Group 2018
Aiheet:
Section 4: Clinical pharmacy services
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535331/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.271
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia